A pharmaceutical composition comprising the compound of formula IIB: ** Formula ** or a pharmaceutically acceptable salt, solvate, stereoisomer and / or ester thereof, wherein: R10a and R10b are independently H or -C1-4 alkyl； R12 is H or -CH3； R13 is - (CH2) 0-3CR17R18NR20R21, - (CH2) 0-3CR17R18NR17C (O) NR20R21, - (CH2) 1-3C (O) R22, - (CH2) 1-3S (O) 2R22 or - (CH2) 1-3-R23； R14 and R15 are each independently H, -C1-4 alkyl or arylalkyl； R17 and R18 are each independently H or -C1-3 alkyl； R19 is H, -C1-4 alkyl or aryl alkyl； R20 and R21 are each independently H, -C1-3 alkyl, -C (O) R17 or -S (O) 2R17； or R20 and R21, taken in conjunction with the nitrogen atom to which they adhere, form a 5-6 membered substituted or unsubstituted heterocyclyl ring containing 1-2 hetero atoms selected from a group consisting of N or O； R22 is H, -C1-3alkyl, -OR19 or -NR20R21； and R23 is a 5-6 membered substituted or unsubstituted heterocyclyl ring containing one-2 hetero atoms selected from a group consisting of N and O； wherein said 5-6 membered substituted or unsubstituted heterocyclyl ring consisting of R20 and R21 and said 5-6 membered substituted or unsubstituted heterocyclyl ring of R23 are each independently substituted or unsubstituted with a C1-2 alkyl, a carrier or pharmaceutically acceptable excipient and at least one additional therapeutic agent.Una composición farmacéutica que comprende al compuesto de la fórmula IIB:**Fórmula** o una de sus sales, solvatos, estereoisómeros y/o ésteres farmacéuticamente aceptables, donde: R10a y R10b son independientemente H o -C1-4 alquilo； R12 es H o -CH3； R13 es -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21, -(CH2)1-3C(O)R22, -(CH2)1-3S(O)2R22 o -(CH2)1-3-R23； R14 y R15 son cada uno independientemente H, -C1-4 alquilo o arilalquilo； R17 y R18 son cada uno independientemente H o -C1-3 alquilo； R19 es H, -C1-4 alquilo o arilo alquilo； R20 y R21 son cada uno independientemente H, -C1-3 alquilo, -C(O)R17 o -S(O)2R17； o R20
